Irvine-based Inari Medical Inc. will be acquired by Stryker Corp. for $4.8 billion. The boards of directors of both companies have approved the transaction, and it’s expected to close in the first quarter of 2025.

Key Takeaways Shares of Inari Medical surged Monday afternoon and again Tuesday morning as reports of an imminent acquisition by Stryker turned into reality.Stryker will acquire Inari in an all-cash deal for $80 per share,

Inari makes mechanical thrombectomy solutions designed to treat peripheral vascular diseases. Stryker said the deal would be complementary to its neurovascular business.

Medical devices behemoth Stryker agreed to buy Inari Medical for $4.9 billion late Monday. Inari stock catapulted on the news.

Stryker said it has a definitive agreement to purchase Inari Medical for $80 per share, a big premium that values the deal at $4.9 billion.

Stryker has entered a definitive agreement to acquire complete issued and outstanding shares of Inari Medical’s common stock for $80 per share in cash, which equates to a total equity value of nearly $4.9bn. Inari is poised to enhance Stryker's footprint in the peripheral vascular sector, particularly in the venous thromboembolism (VTE) market.

We recently compiled a list of the Investor Optimism Boosts Jump of These 10 Stocks. In this article, we are going to take a look at where Inari Medical Inc. (NASDAQ:NARI) stands against the other stocks.

Medical-device maker Stryker on Monday agreed to acquire Inari Medical , which makes devices that treat patients with venous diseases, in an all-cash deal worth $4.9 billion.

Stryker announces agreement to acquire Inari Medical for $4.9 billion, resulting in a 21% jump in Inari's shares.

Stryker said its planned acquisition of Inari Medical would strengthen its position in the peripheral vascular market.